DR. DAVID BAR-OR, MD
Medical Practice at Oxford Ln, Englewood, CO

7070937, Jul 4, 2006

Mar 29, 2001

09/820416

David Bar-Or - Englewood CO, US
Edward Lau - Boulder CO, US

Ischemia Technologies, Inc. - Waltham MA

G01N 33/53, G01N 33/537, G01N 33/543, C12Q 1/50

435 71, 435 17, 435 792

The present invention teaches a marker useful for detection and measurement of free radical damage. Specifically, the invention takes advantage of alterations which occur to the N-terminus of the albumin molecule, a circulating protein in human blood, in the presence of free radicals. These alterations effect the ability of the N-terminus of the albumin molecule to bind metals. Methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of an albumin-containing sample, analysis and measurement of the ability of albumin to bind exogenous cobalt, detection and measurement of the presence of copper in a purified albumin sample and use of an immunological assay specific to the altered form of serum albumin which occurs following free radical damage. Also taught by the present invention is the use of the peptide Asp Ala His Lys and the compound Asp-Ala-His-Lys-R, wherein R is any chemical group capable of producing a detectable signal when a metal ion capable of binding to the N-terminus of naturally-occurring albumin is bound to the compound, for detection and quantitation of the marker. Methods of the present invention also include use of the marker as a “biochemical tag,” thereby allowing for sensitive detection and measurement of the efficacy of clinical drugs and therapeutics which result in the generation of free radicals or which act to limit free radical damage.

2010032, Dec 23, 2010

Jun 22, 2010

12/820325

David Bar-Or - Englewood CO, US

DMI ACQUISITION CORP. - Greenwood Village CO

A61K 31/661, A61K 31/58, A61P 3/10, A61P 9/10, A61P 9/12, A61P 29/00, A61P 7/10, A61P 11/00, A61P 17/00, A61P 13/12

514114, 514171

The invention provides a method of treating a disease or condition mediated by vascular hyperpermeability in an animal. The method comprises administering an amount of a danazol compound effective to inhibit vascular hyperpermeability and an amount of a second drug effective to treat the disease or condition. The invention further provides a method of inhibiting vascular hyperpermeability when it is a side effect caused by administration of a drug to, or another treatment of, an animal. The method comprises administration of an amount of a danazol compound effective to inhibit the vascular hyperpermeability. The invention also provides a method of modulating the cytoskeleton of endothelial cells in an animal comprising administering an amount of a danazol compound and an amount of a second drug effective to modulate the cytoskeleton. The present invention also relates to pharmaceutical compositions and kits comprising a danazol compound and a second drug.

2013030, Nov 14, 2013

Jul 12, 2013

13/940374

David Bar-Or - Englewood CO, US

A61K 38/12

514 211

The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration of the diketopiperazine, the prodrug or the pharmaceutically-acceptable salt according to a method of the invention. The diketopiperazines have the formula given in the application.

2010032, Dec 23, 2010

Jun 22, 2010

12/820398

David Bar-Or - Englewood CO, US

DMI ACQUISITION CORP. - Greenwood Village CO

A61K 31/58, A61P 3/10, A61P 9/10, A61P 9/12, A61P 11/00, A61P 27/02, A61P 7/10, A61P 43/00

514176

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.

2008016, Jul 10, 2008

Dec 28, 2007

11/966293

David Bar-Or - Englewood CO, US
Leonard T. Rael - Aurora CO, US

DMI BIOSCIENCES, INC. - Aurora CO

A61K 31/195, A61P 29/00

514561

The invention provides therapeutic methods and products for the treatment of inflammation, inflammatory diseases and conditions, and proliferative diseases and conditions. The invention also provides methods and products for inhibiting inflammation in excised cells, tissues and organs. The invention further provides oral care methods and products for the treatment of the tissues of an animal's mouth. Finally, the invention provides personal care methods and products for the treatment of the skin of an animal. All of these methods and products utilize N-acyl-L-aspartic acid or an ester or pharmaceutically-acceptable salt thereof.

5771327, Jun 23, 1998

Nov 18, 1996

8/749957

David Bar-Or - Englewood CO
James S. Kimmel - Littleton CO
Francis A. Roth - Arvada CO

Optical Biopsy - Knoxville TN

G02B 636

385139

A fiber optic probe protector for protecting a fiber optic probe such that sterilization of the probe after each use is not necessary. The fiber optic probe protector includes a sheath, a window and a handle. The sheath defines a tubular configuration, a first end, and a second end and the window is mounted in the first end of the sheath. The handle defines a first end, a second end, an interior cavity and a locking means. The second end of the sheath is mounted to the first end of the handle and the interior cavity of the handle and the sheath provide a passage for a fiber optic probe therethrough such that the face of the probe abuts against the window. The locking means locks the fiber optic probe in position. The fiber optic probe protector also includes a vacuum assembly which when hooked to a vacuum removes secretions or fluid from the surface to be analyzed with the probe.

2012005, Mar 8, 2012

Sep 7, 2011

13/227098

David Bar-Or - Englewood CO, US

DMI ACQUISITION CORP. - Greenwood Village CO

A61K 38/12, A61P 27/02, A61P 17/00, B65D 69/00, A61P 9/12, A61P 25/00, A61P 13/12, A61P 9/10, A61P 11/00

514 15, 514 211, 514 19, 514 208, 514 186, 514 157, 514 177, 514 154, 206570

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.The invention further provides a kit. The kit comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.

7973008, Jul 5, 2011

Sep 18, 2009

12/562136

David Bar-Or - Englewood CO, US

A61K 38/00

514 2, 530300

The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention.

2005002, Jan 27, 2005

May 30, 2002

10/477384

Raphael Bar-Or - Denver CO, US
David Bar-Or - Englewood CO, US
C. Curtis - Penylan Cardiff, GB

G01N033/48

702019000

A method and system are disclosed for detecting a medical condition wherein a blood or plasma sample is combined with a metal such as cobalt and optically analyzed for an optical distinction that identifies the medical condition. The invention is useful for diagnosing medical conditions such as ischemia. Moreover, the diagnoses of patient samples according to the invention may be enhanced by developing a mathematical model based on signal processing techniques such as principal component analysis on the data obtained in patient studies.

8586568, Nov 19, 2013

Mar 25, 2011

13/072568

David Bar-Or - Englewood CO, US

Ampio Pharmaceuticals, Inc. - Greenwood Village CO

A01N 45/00, A01N 43/80, A61K 31/56, A61K 31/58, A61K 31/42

514169, 514172, 514176, 514177, 514379

The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.